Pneumocystis Jirovecii Pneumonia

Clinical Info HIV

• Overview of management of PJP as an opportunistic infection including diagnosis, expected presentation and treatment recommendations

1. Which of the following CD4 counts is a risk factor for PJP?

a) <50 cells/ mm³ 

b) <100 cells/ mm³ 

c) <200 cells/ mm³ 

d) <500 cells/ mm³

2. Which of the following signs/symptoms is NOT consistent with PJP? 

a) Productive cough

b) Fever 

c) Ground glass infiltrates 

d) Chest discomfort  

3. Which of the following patients should receive primary prophylaxis for PJP? 

a) Patient on ART and CD4 = 500 cells/ mm³

b) Patient not on ART and CD4 =300 cells/ mm³

c) Patient not on ART and CD4=100 cells/ mm³

d) None of the above - Primary prophylaxis is not indicated due to low rates of mortality 

4. Which of the following agents is recommended for PJP prophylaxis? 

a) Azithromycin  

b) Ciprofloxacin 

c) Prednisone

d) SMX/TMP

5. Your patient is currently receiving secondary prophylaxis following their PJP diagnosis. When should therapy be discontinued? 

a) Once CD4>200 cells/ mm³ 

b) Once HIV VL undetectable 

c) CD4 >500 cells/ mm³ 

d) None of the above – secondary prophylaxis recommended lifelong in all patients